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A
 
BSTRACT
Background:
 
This is the first report about the pharma-
cokinetics (PK) of pranlukast in children. The aim of the
present study was to assess the PK parameters of pran-
lukast in children and to compare them with those in
adults.
 
Methods:
 
Six healthy adult male volunteers and 22
children with bronchial asthma at 3–14 years of age
were enrolled in the study. Both 225 and 112.5 mg
pranlukast hydrate dry syrup was administered orally
to adults, whereas 3.5 mg/kg pranlukast hydrate dry
syrup was given to children. Blood samples were
obtained at approximately 20 time points per adult
(
 
n
 
 = 121) and at two or three time points per child
(
 
n
 
 = 54). Population PK analysis was performed using
 
NONMEM
 
 (Globomax, Hanover, MD, USA). The
concentration–time-course of pranlukast was described
by using a one-compartment model with first-order
absorption. The robustness of the final model was
evaluated using 200 bootstrap samples.
 
Results:
 
Apparent clearance (CL/F) was 1.81 and
1.14 L/h per kg in children and adults, respectively.
According to subgrouping of children, no significant
difference was observed in CL/F between infants (3–6
years of age) and schoolchildren (7–14 years of age).
The interindividual variability of CL/F accounted for
48.7%. The additive and proportional residual vari-
ability was 7.33 ng/mL and 73.8%, respectively. All
fixed effect parameters fell within 10% of the boot-
strapped mean.
 
Conclusions:
 
Compared with adults, children showed
a higher CL/F and more rapid elimination after inges-
tion of pranlukast hydrate dry syrup. However, no
significant variation was seen in CL/F between infants
and schoolchildren.
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I
 
NTRODUCTION
 
Pranlukast was developed as a specific receptor antago-
nist of leukotriene C
 
4
 
, D
 
4
 
 and E
 
4
 
.
 
1
 
 It has been reported
that administration of pranlukast is associated with
inhibition of early and late-phase bronchoconstriction,
 
2–4
 
airway hyperresponsiveness
 
4,5
 
 and eosinophil infiltration
into airways,
 
6,7
 
 evolving into effective prevention of
exercise-induced asthma.
 
8
 
 However, there has been no
report on the pharmacokinetics of pranlukast in children.
This is because a relatively large number of blood
samples is required for traditional pharmacokinetic
studies, thereby preventing exploration the pharmaco-
kinetics of pranlukast in children due to ethical and
practical reasons. However, using the population
pharmacokinetic approach, only a few plasma concen-
tration measurements per patient are necessary for
adequate analysis of the data. The objective of the
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present study was to estimate the pharmacokinetic
parameters of pranlukast in children with bronchial
asthma and to compare these parameters with those in
healthy adult volunteers.
METHODS
Studies on healthy adult male volunteers (study 1) and
on children with asthma (study 2) were conducted
according to two different protocols. The study protocols
were reviewed and approved by the Institutional Review
Boards of each clinical study site. Written informed
consent was obtained from all adult subjects in study 1.
In study 2, written informed consent was obtained from
parents or legal guardians of all children. In addition,
informed assent was obtained from children over 8 years
of age.
Study 1
In study 1, six healthy males aged between 21 and
36 years participated (Table 1). All subjects received
single oral doses of either 225 or 112.5 mg pranlukast.
Blood samples were obtained at 1, 2, 3, 4, 5, 6, 7, 8,
10, 12 and 24 h after drug administration. The total
number of data points reached 121. The plasma con-
centration of pranlukast in adults was determined using
high-performance liquid chromatography (HPLC), fol-
lowing the assay procedures stated below. Initially,
pranlukast was extracted from plasma with ethanol and
the supernatant was evaporated to dryness. The residue
was dissolved in 1% tartaric acid solution followed by
extraction with ethyl acetate. The organic layer was
evaporated to dryness; subsequently, the residue was
dissolved in ethanol and ethyl acetate and the resultant
solution was then applied to a SEP-PAK Si column
(Waters, Milford, MA, USA). After the eluate was evapor-
ated to dryness, the residue was reconstituted with mobile
phase and injected into the HPLC system. The linear
range of the concentration curve was 10–1000 ng/mL,
with the lower limit of quantitation being 10 ng/mL.
Study 2
In study 2, 22 patients with bronchial asthma aged
between 3 and 14 years of age were involved (Table 1).
There were 11 infants (3–6 years old) and 11 school-
children (7–14 years old). Pranlukast hydrate dry syrup
was administered orally twice a day at 3.5 mg/kg. The
blood sampling was conducted at two time points: from
4 to 6 h and from 8 to 10 h after drug administration.
If possible, a third sampling was performed from 1 to
3 h after administration. In total, 54 data points were
used. The plasma concentration of pranlukast was deter-
mined by liquid chromatography connected to a tandem
mass spectrometer (LC/MS/MS). Pranlukast was extracted
from plasma by liquid–liquid extraction with 0.3 mol/L
potassium dihydrogen phosphate solution and ethyl
acetate and the organic layer was then evaporated to
dryness. The residue was dissolved in mobile phase and
was then injected into the LC/MS/MS system. The linear
range of the concentration curve was 2–200 ng/mL,
with the lower limit of quantitation being 2 ng/mL. Cross-
validation demonstrated that HPLC and LC/MS/MS
generated equivalent results.
Data analysis
Using the NONMEM program (double-precision NONMEM
Ver. V level 1.1; Globomax, Hanover, MD, USA),
estimates were obtained for the population means of
pharmacokinetic parameters, interindividual variability in
these parameters and residual variability between the
observed and predicted concentrations of pranlukast
hydrate. The concentration–time-course of pranlukast
was presented using a one-compartment model with
first-order absorption and elimination. The pharmaco-
kinetics of pranlukast were described by the following
equation:
where Cij is the plasma concentration measured in the
jth subject at the ith time point (tij), Dj, CLj, and Kaj are
the dose, total body clearance and first-order absorption
Cij =
Kaj •Dj
 (exp (–
CLj
• ij – t lagj) )
– exp (–Kaj •(tij – tlagj) ) [1]
Vd/Fj •(Kaj – CLj/Vd) Vd
Table 1 Demographic characteristics of the subjects
Study 1 Adults Study 2 Children
Disease Healthy Asthma
Dose 1.125, 2.25 g/person 35 mg/kg
No. subjects 6 (6 M) 22 (14 M, 8 F)
No. time points 121 54
Age (years)* 26.0 (21–36) 6.5 (3–14)
Bodyweight (kg)* 66.6 (55.4–76.3) 24.0 (12.3–53.0)
*Data for age and bodyweight are the average with the range given
in parentheses.
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rate constant in the jth subject, respectively, and Vd/Fj, Fj
and tlagj are an apparent volume of distribution, bio-
availability after oral administration, and lag time of
absorption, respectively.
The interindividual variabilities in pharmacokinetic
parameters were modeled with proportional error
according to the following equation:
where Pj is the parmacokinetic parameter for jth
individual, 
~
Pj is the jth individual parameter with the
regression model and ηj is an independently distributed
random variable with a mean of zero and variance ω2.
The intrasubject residual variability was also modelled
with the combination of additive and proportional error
models according to the following equation:
where Cij is the ith measured plasma concentration in
the jth subject, 
~
Cij is  the  corresponding  predicted  plasma
concentration and ε1ij and ε2ij are residual variability
terms, representing independent identically distributed
statistical errors with a mean of zero and variance σ2.
The model for the residual variability was determined
from preliminary analysis.
To test the significance of various factors affecting the
pharmacokinetic parameters, we used the value of objec-
tive function determined in the NONMEM fitting routine.
The difference in objective function values obtained by
comparing each model is asymptotically distributed as
Chi-squared with degree of freedom equal to the differ-
ence in the number of parameters between the two
models. To identify potentially significant factors, the
difference in the objective function associated with
P < 0.05 was required.
The accuracy and robustness of the final model were
assessed by using a bootstrap method.9–11 Two hundred
data sets were reconstructed by resampling six adults
and 22 children from the original data. The mean
parameter estimates obtained from 200 bootstrap repli-
cations were compared with those obtained from the
original dataset.
The dose of pranlukast was 7 mg/kg per day twice a
day in children, which was approximately the same for
adults (450 mg/day) in terms of dose per bodyweight.
Accordingly, the dose administered for children and the
results obtained from the population analysis permitted
us to simulate the concentration–time profile for both
adults and children.
RESULTS
The plasma concentrations of pranlukast used for the
population pharmacokinetic analysis are shown in
Fig. 1. The basic model was tested initially with age as a
covariate. Model 2 presenting the difference of apparent
clearance (CL/F) between all children (< 15 years of
age) and adults produced a significant improvement in
the fit of the model to the data. A further improvement
was not observed when the difference in CL/F of the
subgroups, namely between infants (3–6 years) and
schoolchildren (7–14 years) was included in the model.
Therefore, Model 2 was selected as the basic model in
the present study. All results are given in Table 2.
At the model-building stage, the following clinical
factors were tested individually as covariates: gender,
concomitant medication of theophylline, total bilirubin,
lactate dehydrogenase and serum creatinine. However,
no clinical factors were found to influence CL/F. These
results are shown in Table 3.
The parameter estimates of the final regression model
are shown in Table 4. The final regression model is pre-
sented below:
CL/F (L/h per kg) = 1.14 × 1.59GE
Apparent distribution volume (Vd/F; L/kg) = 1.53
Absorption rate constant (Ka; /h) = 0.493
Lag time of absorption (tlag; h) = 0.981
with GE = 1 for children and 0 for adults.
Cij =
~Cij (1 + ε1ij) + ε2ij [3]
Pj = P
~j (1 + ηj ) [2]
Fig. 1 Time after administration versus plasma concentrations
of pranlukast in six adults receiving 225 mg pranlukast () and
in 22 children receiving 3.5 mg/kg ().
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The interindividual variabilities in CL/F, Ka and t
 
lag
 
were 48.7, 21.6 and 15.7%, respectively. The additive
and proportional residual variabilities accounted for
7.33 ng/mL and 73.8%, respectively. The relationship
between observed and predicted values obtained by
Bayesian estimation is illustrted in Fig. 2.
The parameter estimates of the final model and the
results of the bootstrap validation step are listed in
Table 5. All structural parameters (
 
θ
 
) were within 10% of
the bootstrapped mean, whereas the variance para-
meters (
 
ω
 
, 
 
σ
 
), except for 
 
ω
 
2
 
, also fell within 10% of the
bootstrapped mean.
Figure 3 illustrates the mean concentration–time
profiles for pranlukast in adults and children predicted
from the final population pharmacokinetic model.
 
D
 
ISCUSSION
 
The objective of the present study was to characterize the
pharmacokinetics of pranlukast in children by using
numerical analysis methodology for sparse data. In
pharmacokinetic analysis, the population approach pro-
vides an advantage by permitting us to extract pharmaco-
kinetic information from sparse or fragmented data,
 
Table 2
 
Determination of the basic model (effect of age on apparent clearance)
Model Equation LLD
 
P
 
1. Simple model CL/F = 
 
θ
 
1
 
Vd/F = 
 
θ
 
2
 
Ka = 
 
θ
 
3
 
t
 
lag
 
 = 
 
θ
 
4
 
2. Does the group ‘children’ influence CL/F?* CL/F = 
 
θ
 
1
 
 × θ
 
5
 
GE
 
25.020 < 0.05
Vd/F = 
 
θ
 
2
 
Ka = 
 
θ
 
3
 
t
 
lag
 
 = 
 
θ
 
4
 
3. Does the age of children influence CL/F?† CL/F = 
 
θ
 
1
 
 × 
 
FAC1 
 
× 
 
FAC2 2.891 NS
Vd/F = 
 
θ
 
2
 
Ka = 
 
θ
 
3
 
t
 
lag
 
 = 
 
θ
 
4
 
*GE for children = 1; GE for adults = 0.
†FAC1 is set to 
 
θ
 
5
 
 if the patient is an infant (3–6 years old) and to 1 otherwise; FAC2 is set to 
 
θ
 
6
 
 if the patient is a schoolchild (7–14 years old)
and to 1 otherwise.
CL/F, apparent clearance; Vd/F, apparent distribution volume; Ka, absorption rate constant; t
 
lag
 
, lag time of absorption.
 
Table 3
 
Effect of individual covariates on apparent clearance
Equation
 
θ
 
5
 
θ6 LLD P
Basic model CL/F = θ1 × θ5GE 1.59
Vd/F = θ2
Ka = θ3
tlag = θ4
GEND θ1 × θ5GE × θ6GEND 1.56 1.13 0.775 NS
THEO θ1 × θ5GE × θ6THEO 1.85 0.828 1.568 NS
TBIL θ1 × θ5GE × θ6TBIL 1.57 1.11 0.325 NS
LDH θ1 × θ5GE × θ6LDH 1.53 1.11 1.915 NS
CRE θ1 × θ5GE × θ6CRE 1.31 1.23 1.320 NS
GEND was designated 0 in males, and 1 in females; THEO was designated 0 in the case of non-coadministration of theophylline and 1 in the
case of coadministration.
TBIL, total bilirubin; LDH, lactate dehydrogenase; CRE, serum creatinine. These were designated 0 in the case of normal values and 1 in the
case of abnormal values.
CL/F, apparent clearance; Vd/F, apparent distribution volume; Ka, absorption rate constant; tlag, lag time of absorption.
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further evolving into our successful assessment of factors
that may influence drug disposition.
The population pharmacokinetic analysis was con-
ducted by comparing a subgroup consisting of infants
from 3 to 6 years of age with another subgroup compris-
ing schoolchildren aged from 7 to 14 years. Age was
treated as a discrete variable, because 22 cases were too
few in number to be treated as a continuous function. In
the present analysis, no significant difference was
observed for CL/F between the two subgroups of infants
and schoolchildren. In contrast, a difference in CL/F was
observed between all children and adults. The CL/F in the
children was 1.59-fold higher than that in adults, indicat-
ing that pranlukast hydrate was eliminated more rapidly
in children than in adults.
It is known that clearance per bodyweight decreases in
parallel with the growth of children following medication
for several types of drugs, such as ketotifen,12
Table 4 Parameters estimated with the final model
Estimates
CL/F = θ1 × θ5GE
θ1 1.14 (0.47–1.81)
θ5 1.59 (1.06–2.12)
ωCL/Φ (%) 48.7
Vd/F = θ2
θ2 1.53 (0.63–2.43)
ωVd/F (%) Fixed
Ka = θ3
θ3 0.493 (0.357–0.629)
ωKa (%) 21.6
tlag = θ4
θ4 0.981 (0.960–1.002)
ωtlag (%) 15.7
Residual variability
Proportional, σ1 (%) 73.8
Additive, σ2 (ng/mL) 7.33
Estimates are given as the mean with 95% confidence intervals in
parentheses.
CL/F, apparent clearance; Vd/F, apparent distribution volume; Ka,
absorption rate constant; tlag, lag time of absorption.
The CL/F of adults: θ1 = 1.14; CL/F of children: θ1 × θ5 = 1.81.
Fig. 2 Observed versus predicted concentrations of pran-
lukast from a Bayesian post hoc analysis of the final model with
121 time points obtained from six adults () and 54 time points
obtained from 22 children ().
Table 5 Results of Bootstrap validation
Parameter Final model* Bootstrap† Difference (%)‡
θ1 1.14   (0.34) 1.07 (0.16) –6.4
θ2 1.53   (0.46) 1.51 (0.41) –1.2
θ3 0.493 (0.069) 0.536 (0.098) 8.8
θ4 0.981 (0.011) 0.982 (0.009) 0.1
θ5 1.59   (0.27) 1.66 (0.31) 4.2
ωCL/F (%) 48.7 47.5 (39.2) –2.4
ωKa (%) 21.6 39.1 (49.9) 81
ωtlag (%) 15.7 14.5 (10.2) –7.7
σ1 (%) 73.8 72.5 (41.1) –1.7
σ2 (ng/mL) 7.33 7.55 (4.80) 3.0
Data show the mean with SEM given in parentheses.
*Obtained from the original dataset.
†Calculated from 200 bootstrap replicates.
‡(Bootstrap value-final model value)/final model value 100%.
CL/F, apparent clearance; Vd/F, apparent distribution volume; Ka, absorption rate constant; tlag, lag time of absorption.
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phenobarbital13 and valproric acid;14 this phenomenon is
likely to be attributed to the higher liver weight relative to
bodyweight in children than in adults.15 Accordingly, it is
postulated that medication with drugs susceptible to pre-
dominant metabolism in the liver demonstrates higher
CL/F in children than in adults. Pranlukast is considered
to be mainly metabolized in the liver because little pran-
lukast hydrate is excreted into the urine. Hence, the
present results are consistent with previous findings.
A possible interaction of pranlukast following con-
comitant use of theophylline, which is frequently used for
the treatment of bronchial asthma, was investigated in
the present study. However, theophylline did not appear
to influence the CL/F of pranlukast.
The mean parameter estimates obtained with the 200
bootstrap replicates of the data were within 10% of those
obtained from the original data, except for the inter-
individual variation of Ka. This may be due to insufficient
data during the absorption phase. This final pharmaco-
kinetic model was useful for the prediction of CL/F.
In conclusion, pranlukast hydrate showed a higher
CL/F and was eliminated more rapidly in children than in
adults. However no significant variation was observed for
CL/F in two child subgroups, namely between infants
(3–6 years) and schoolchildren (7–14 years).
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